RVNC
Revance Therapeutics, Inc.
NASDAQ: RVNC · HEALTHCARE · BIOTECHNOLOGY
$3.65
+0.00% today
Updated 2026-06-04
Market cap
$381.02M
P/E ratio
—
P/S ratio
1.48x
EPS (TTM)
$-3.34
Dividend yield
—
52W range
$0 – $0
Volume
4.1M
Revance Therapeutics, Inc. (RVNC) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+17.8%
Last 4 quarters
Revenue YoY growth
+5.5%
Most recent quarter
EPS YoY growth
+77.3%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-36.3%
Last 1 reports
Positive reaction rate
0%
0 of 1 quarters
Largest single-day move
-36.3%
2024-11-07
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2024-11-07 | $-0.37 | +2.6% | $5.81 | $3.70 | -36.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2024-09-30 | $-0.38 | $-0.37 | +2.6% | $59.88M | +5.5% |
| 2024-06-30 | $-0.53 | $-0.36 | +32.1% | $65.39M | +12.5% |
| 2024-03-31 | $-0.75 | $-0.58 | +22.7% | $51.94M | +5.3% |
| 2023-12-31 | $-0.72 | $-0.62 | +13.9% | $69.80M | +39.8% |
| 2023-09-30 | $-0.85 | $-1.63 | -91.8% | $56.78M | +95.7% |
| 2023-06-30 | $-0.78 | $-0.80 | -2.6% | $58.13M | +104.9% |
| 2023-03-31 | $-0.70 | $-0.74 | -5.7% | $49.33M | +95.3% |
| 2022-12-31 | $-0.95 | $-0.95 | +0.0% | $49.92M | +92.4% |
| 2022-09-30 | $-0.89 | $-1.17 | -31.5% | $29.02M | — |
| 2022-06-30 | $-0.86 | $-0.88 | -2.3% | $28.37M | — |
| 2022-03-31 | $-0.83 | $-0.94 | -13.3% | $25.26M | — |
| 2021-12-31 | $-1.00 | $-0.93 | +7.0% | $25.95M | — |
Frequently asked questions
Has Revance Therapeutics, Inc. beaten earnings estimates?
Revance Therapeutics, Inc. has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, averaging a +17.8% surprise over the last 4. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.
How does RVNC stock react to earnings?
RVNC has moved an average of -36.3% the day after earnings over its last 1 reports, finishing higher after 0 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.
What is Revance Therapeutics, Inc.'s revenue growth rate?
Revance Therapeutics, Inc. reported year-over-year revenue growth of +5.5% in its most recent quarter, with EPS up +77.3%. EPS outpacing revenue is operating leverage at work, meaning profit is compounding faster than sales.